Iradimed (IRMD) Net Income towards Common Stockholders (2013 - 2026)

Iradimed has reported Net Income towards Common Stockholders for 14 years, with the latest figure at $5.2 million in Q2 2026.

• Net Income towards Common Stockholders for Q2 2026 came in at $5.2 million, down 9.63% year-over-year; the trailing twelve-month figure through Jun 2026 was $23.0 million (up 15.13% YoY), and the FY2025 annual result was $22.4 million, up 20.87% from the prior year.
• Net Income towards Common Stockholders declined to $5.2 million in Q2 2026, from $5.8 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $6.4 million in Q4 2025 and troughed at $2.5 million in Q1 2022.
• A 5-year average of $4.5 million and a median of $4.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The widest annual swing landed in 2022, when Net Income towards Common Stockholders jumped 120.53%; it then decreased 15.13% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $3.7 million in 2022, then fell by 15.13% to $3.1 million in 2023, then jumped by 42.69% to $4.4 million in 2024, then surged by 43.12% to $6.4 million in 2025, then declined by 18.05% to $5.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $5.2 million in Q2 2026, $5.8 million in Q1 2026, and $6.4 million in Q4 2025.